CAR T-cell therapy is rapidly expanding beyond blood cancers, with researchers making significant progress in treating solid tumors through next-generation cell engineering and precision immunotherapy.
The global market is projected to grow from USD 1.42 billion in 2025 to USD 1.83 billion in 2026, reaching USD 17.98 billion by 2035 at an impressive 28.9% CAGR.
North America leads with a 43% market share, backed by a strong clinical trial ecosystem, biotech investments, and regulatory support.
Meanwhile, Asia Pacific holds 22% of the market and is expected to register the fastest growth as biotechnology investments, government support, and cancer research continue accelerating across China, India, Japan, and other emerging economies.
Among target antigens, HER2 accounts for 19% of the market, while Claudin 18.2 (CLDN18.2) is emerging as one of the fastest-growing targets for gastric and pancreatic cancers.
Source: https://www.towardshealthcare.com/insights/car-t-cell-therapy-for-solid-tumors-market-sizing
By tumor type, gastrointestinal cancers lead with 27% market share, while glioblastoma is expected to witness the strongest future growth as researchers develop therapies capable of overcoming the blood-brain barrier.
Second-generation CAR T-cell therapies dominate with 48% market share, whereas fourth-generation TRUCKs are gaining momentum by improving immune activation within the tumor microenvironment.
Autologous CAR T-cell therapy represents 81% of the market, while allogeneic “off-the-shelf” therapies continue attracting investment due to faster manufacturing and lower treatment costs.
Industry leaders including CARsgen Therapeutics, BioNTech, Gilead Sciences (Kite Pharma), Novartis, Bristol Myers Squibb, Legend Biotech, Autolus Therapeutics, Immatics, Atara Biotherapeutics, and Noile-Immune Biotech are advancing dual-target CARs, gene-editing technologies, armored CAR-T platforms, and next-generation solid tumor pipelines.
Artificial Intelligence is becoming a critical enabler by identifying novel tumor antigens, optimizing CAR receptor design, predicting treatment response, and accelerating clinical trial development through advanced genomics and machine learning.
With increasing cancer incidence, strong government and biotech investments, expanding clinical trials, and continuous breakthroughs in precision oncology, CAR T-cell therapy for solid tumors is emerging as one of the most transformative areas in modern cancer care.
Explore key market numbers, growth opportunities, and competitive insights. Access your FREE sample report now: https://www.towardshealthcare.com/download-sample/6999
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium